At UCB, our aim is to amplify the power of scientific innovation through digital transformation, ensuring we deliver the best individual experience so patients can live their best lives. As part of that effort, we are integrating artificial intelligence (AI) across the research and development organization to bring accelerated solutions to patients with unmet needs. 

UCB’s Head of Digital Business Transformation, Colin Lake speaks to the current landscape in digital business transformation and neurology.

To better understand the experiences of Hispanic people with epilepsy and to improve our collective effort to break down barriers to equitable health outcomes, UCB is working with patients and their families, as well as health equity experts. Learn more.

During my time in the Navy, I developed a strong sense of purpose, service and mission. After fulfilling my service obligation, I was eager to find another career that continued to allow me to do something larger than myself. I found at UCB, a company that makes medicines to help improve the lives of people living with epilepsy, a different type of service: service to patients.

UCB spoke with caregiver, Debbie, about her experience caring for her daughter living with epilepsy and its personal impact on her, as well as the important role of telehealth in epilepsy care. Her story speaks to the challenges many caregivers face when looking after their loved ones and the importance of prioritizing their own mental health. As one of UCB’s Epilepsy Advocates and as a patient advocate for the Epilepsy Foundation, Debbie supports others living with epilepsy and their families throughout their healthcare journey. In these roles, she helps many find access to the right mental health resources, which she says can be a “game changer” for both epilepsy patients and their loved ones.

UCB is excited to exchange ideas at ACR Convergence, Nov. 3-9, 2021. Learn more about our presence at the conference and work in rheumatology from Dr. Jeffrey Stark, Head of Immunology Medical Affairs U.S.

UCB spoke with Tim, who has been living with epilepsy since 1979 while he was on active duty. His story focuses on the challenges that epilepsy brings but also shares how his new, positive outlook on life has changed the way he lives. As a member of UCB’s Epilepsy Advocate program, Tim helps to support other epilepsy patients and has been a resource for others during their journey with epilepsy.

As innovators in the healthcare industry, UCB and The Innovation and Value Initiative (IVI) believe recognizing patient voices in value assessments is important. In our recent Voices on Values series, our Head of U.S. HEOR Strategy, Edward Lee, sat down with Jennifer Bright, Executive Director at IVI to discuss how we can ensure all patient voices are captured in value assessments. Learn more about their conversation.

In order to build a world where care is more accessible to every patient, you have to put patients at the center of everything you do. UCB and The Innovation and Value Initiative (IVI) are focused on developing strategies that make patients the focal point of value assessments. Learn more about our patient centered approach from our Head of U.S. HEOR Strategy, Edward Lee, and IVI Executive Director Jennifer Bright.

UCB today announced new data from a network meta-analysis (NMA) demonstrating that bimekizumab was associated with the lowest number needed to treat (NNT) to achieve Psoriasis Area and Severity Index (PASI) 90 and PASI 100 skin clearance levels compared with 12 other approved biologic therapies used for moderate to severe plaque psoriasis within 16 weeks. These results were presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2021, October 18-21.